Key Insights

Highlights

Treatment Research

3 treatments under study, led by Plerixafor

Research Leaders

5 sponsors active, led by Dana-Farber Cancer Institute

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01339039Phase 1Terminated

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Showing all 1 trials

Research Network

Common Treatments

  • Plerixafor1
  • Bevacizumab1
  • Surgery1

Active Sponsors

  • Dana-Farber Cancer Institute1
  • Massachusetts General Hospital1
  • Patrick Y. Wen, MD1
  • Brigham and Women's Hospital1
  • Genzyme, a Sanofi Company1

Related Conditions

  • Mixed Anaplastic Oligoastrocytoma Aoa1
  • High Grade Glioma Glioblastoma Gbm1
  • Anaplastic Oligodendroglioma Ao1
  • Anaplastic Astrocytoma Aa1

Activity Timeline